Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
|Articles|February 1, 1998
- ONCOLOGY Vol 12 No 2
- Volume 12
- Issue 2
NCI Announces New Cancer Survivorship Training Program
In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues survivors face.
Advertisement
In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues survivors face.
The training program was developed by NCIs Office of Cancer Information, Communication, and Education in collaboration with Ortho Biotech Inc., the National Coalition for Cancer Survivorship, and cancer organizations nationwide.
To obtain a free copy of the training program, please contact the NCIs Cancer Information Service at 1 (800) 4-CANCER [1 (800) 422-6237].
Articles in this issue
almost 29 years ago
Quantitative Assay Provides Effective Method for Monitoring Bladder Canceralmost 29 years ago
Extension of Human Cell Life-Span Reportedalmost 29 years ago
Abnormal DNA Structures May Hold Key to Early Cancer Detection, Treatmentalmost 29 years ago
SGO Clinical Practice Guidelines: Introductory Remarksalmost 29 years ago
ACS Issues Action Proposal on Prostate Cancer in African-Americansalmost 29 years ago
HMO vs Fee-for-Service Care for Breast Canceralmost 29 years ago
Revised Manual on Radiation Oncology Nursing Availablealmost 29 years ago
ONS Publishes Manual on Psychosocial Aspects of Oncology Carealmost 29 years ago
Cigarette Smoking Among Adults-United States, 1995Advertisement
Related to this article
Rutika Mehta, MD, MPH, discusses perioperative durvalumab plus FLOT and first-line options for patients with low or negative PD-L1 gastroesophageal cancer.
Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab plus FLOT.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
4
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
5